MCID: THY123
MIFTS: 48

Thyroid Gland Follicular Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Follicular Carcinoma

MalaCards integrated aliases for Thyroid Gland Follicular Carcinoma:

Name: Thyroid Gland Follicular Carcinoma 12 15
Follicular Adenocarcinoma, Well Differentiated 12
Follicular Thyroid Carcinoma 12
Adenocarcinoma, Follicular 43
Follicular Adenocarcinoma 12
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3962
MeSH 43 D018263
NCIt 49 C8054
SNOMED-CT 67 255028004
UMLS 71 C0206682

Summaries for Thyroid Gland Follicular Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that has material basis in follicular cells.

MalaCards based summary : Thyroid Gland Follicular Carcinoma, also known as follicular adenocarcinoma, well differentiated, is related to fetal adenoma and graves disease 1. An important gene associated with Thyroid Gland Follicular Carcinoma is MIR222 (MicroRNA 222), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Endometrial cancer. The drugs Bortezomib and Vorinostat have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and endothelial, and related phenotypes are endocrine/exocrine gland and nervous system

Related Diseases for Thyroid Gland Follicular Carcinoma

Diseases related to Thyroid Gland Follicular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 344)
# Related Disease Score Top Affiliating Genes
1 fetal adenoma 30.8 TG CALCA
2 graves disease 1 30.8 TSHR TG SLC5A5 CALCA
3 endemic goiter 30.7 TSHR TG CHST14 CALCA
4 familial thyroid dyshormonogenesis 30.7 TG SLC5A5
5 thyroid carcinoma, familial medullary 30.7 TG RET NKX2-1 CALCA
6 papillary thyroid microcarcinoma 30.7 TSHR TG NKX2-1 CALCA
7 hyperthyroidism 30.6 TSHR TG CALCA
8 parathyroid adenoma 30.6 RET LGALS3 CALCA
9 parathyroid carcinoma 30.6 RET LGALS3 CALCA
10 nontoxic goiter 30.6 TSHR TG CALCA
11 papillary adenocarcinoma 30.6 NKX2-1 KRT19 HRAS
12 colloid adenoma 30.5 TG LGALS3
13 substernal goiter 30.5 TG CALCA
14 congenital hypothyroidism 30.4 TSHR TG SLC5A5 PAX8 NKX2-1
15 nonencapsulated sclerosing carcinoma 30.4 TG RET CALCA
16 adenoma 30.4 TSHR TG RET LGALS3
17 struma ovarii 30.4 TSHR TG RET NKX2-1 NCOA4 KRT19
18 benign teratoma 30.4 TG PAX8 NKX2-1
19 papillary carcinoma 30.3 TSHR TG RET PPARG PAX8 NKX2-1
20 thyroid tumor 30.3 TG RET LGALS3 HRAS
21 follicular adenoma 30.3 TSHR TG RET PPARG PAX8 NKX2-1
22 pendred syndrome 30.2 TG SLC5A5 PAX8
23 differentiated thyroid carcinoma 30.2 TSHR TG RET PPARG PAX8 NKX2-1
24 thyroiditis 30.1 TSHR TG RET NKX2-1 NCOA4 HRAS
25 renal cell carcinoma, nonpapillary 30.1 RET PAX8 NKX2-1 MIR199A1 MIR17 MIR144
26 thyroid cancer, nonmedullary, 2 30.1 TSHR TG PPARG PAX8 LGALS3 HRAS
27 hypothyroidism, congenital, nongoitrous, 2 30.1 TSHR TG SLC5A5 PAX8 NKX2-1 LGALS3
28 endocrine gland cancer 30.1 RET MIR222 MIR199A1 MIR183 MIR17 MIR144
29 malignant struma ovarii 30.1 TG RET NKX2-1 NCOA4 LGALS3 KRT19
30 hypothyroidism 29.9 TSHR TG SLC5A5 RET PAX8 NKX2-1
31 ovarian disease 29.9 PPARG MIR222 MIR199A1 MIR17
32 thyroid gland medullary carcinoma 29.9 TPCN1 TG RET PAX8 NCOA4 MIR222
33 hashimoto thyroiditis 29.9 TSHR TG RET NCOA4 LGALS3 KRT19
34 renal cell carcinoma, papillary, 1 29.8 RET PAX8 MIR199A1 KRT19 HRAS
35 thyroid carcinoma 29.8 TSHR TG RET NKX2-1 NCOA4 LGALS3
36 multinodular goiter 29.8 TSHR TG RET PAX8 NKX2-1 KRT19
37 ovarian germ cell teratoma 29.8 TG RET NKX2-1 NCOA4 LGALS3 KRT19
38 nodular goiter 29.5 TSHR TG SLC5A5 RET MIR199A1 LGALS3
39 goiter 29.4 TSHR TG SLC5A5 RET PAX8 NKX2-1
40 thyroid gland cancer 28.6 TSHR TPCN1 TG SLC5A5 RET PPARG
41 thyroid gland disease 28.3 TSHR TPCN1 TG SLC5A5 RET PPARG
42 thyroid gland anaplastic carcinoma 27.9 TSHR TPCN1 TG SLC5A5 RET PPARG
43 familial papillary or follicular thyroid carcinoma 12.6
44 trabecular follicular adenocarcinoma 12.4
45 papillary follicular thyroid adenocarcinoma 12.3
46 thyroid carcinoma, hurthle cell 11.7
47 thyroid gland hurthle cell carcinoma 11.5
48 multicentric papillary thyroid carcinoma 10.7 TG RET
49 thyroid gland mucoepidermoid carcinoma 10.6 TG CALCA
50 spindle epithelial tumor with thymus-like differentiation tumor 10.6 TG CALCA

Graphical network of the top 20 diseases related to Thyroid Gland Follicular Carcinoma:



Diseases related to Thyroid Gland Follicular Carcinoma

Symptoms & Phenotypes for Thyroid Gland Follicular Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Follicular Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 HRAS KRT19 NKX2-1 PAX8 PPARG RET
2 nervous system MP:0003631 10 CHST14 HRAS KRT19 LGALS3 NKX2-1 PAX8
3 neoplasm MP:0002006 9.87 HRAS KRT19 LGALS3 NKX2-1 PPARG RET
4 no phenotypic analysis MP:0003012 9.7 HRAS KRT19 NKX2-1 PAX8 PPARG RET
5 reproductive system MP:0005389 9.61 CHST14 KRT19 LGALS3 NKX2-1 PAX8 PPARG
6 skeleton MP:0005390 9.32 CHST14 HRAS KRT19 LGALS3 NKX2-1 PAX8

Drugs & Therapeutics for Thyroid Gland Follicular Carcinoma

Drugs for Thyroid Gland Follicular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
2
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
3
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
4
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
5
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
6
Durvalumab Approved, Investigational Phase 2 1428935-60-7
7
Ipilimumab Approved Phase 2 477202-00-9
8
nivolumab Approved Phase 2 946414-94-4
9
Iodine Approved, Investigational Phase 2 7553-56-2 807
10
Lenvatinib Approved, Investigational Phase 2 417716-92-8
11
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
12
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
13
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
14
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
15
Trametinib Approved Phase 2 871700-17-3 11707110
16
Salmon calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
17
Pembrolizumab Approved Phase 2 1374853-91-4
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
19
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
20
Tremelimumab Investigational Phase 2 745013-59-6
21
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
22
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
23
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
24 Deoxyglucose Phase 2
25 Histone Deacetylase Inhibitors Phase 2
26 Anti-Bacterial Agents Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Antimetabolites Phase 2
29 Mitogens Phase 2
30 Fluorides Phase 2
31 Endothelial Growth Factors Phase 2
32 Antiviral Agents Phase 2
33 Antibodies, Monoclonal Phase 2
34 cadexomer iodine Phase 2
35 Immunoglobulins Phase 1, Phase 2
36 Antibodies Phase 1, Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38 Angiogenesis Inhibitors Phase 2
39 Immunologic Factors Phase 1, Phase 2
40 Hormones Phase 1, Phase 2
41 Trace Elements Phase 2
42 Anti-Infective Agents Phase 2
43 Anti-Infective Agents, Local Phase 2
44 Nutrients Phase 2
45 Micronutrients Phase 2
46 Katacalcin Phase 2
47 calcitonin Phase 2
48 Fluorodeoxyglucose F18 Phase 2
49 Protein Kinase Inhibitors Phase 2
50 Radiopharmaceuticals Phase 2

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
2 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
3 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
4 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
5 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
6 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
7 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
8 Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas Completed NCT00287287 Phase 2 Lenalidomide
9 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
10 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
11 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
12 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
13 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
14 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
15 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib S-malate
16 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Recruiting NCT02152995 Phase 2 Trametinib
17 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
18 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
19 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
20 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
21 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
22 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
23 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Active, not recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
24 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib
25 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
26 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
27 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
28 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
29 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
30 Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. Unknown status NCT01075269
31 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
32 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
33 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
34 Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone Completed NCT01441154
35 Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions Completed NCT00001452
36 Studies on Thyroid Nodules and Thyroid Cancer Recruiting NCT00001160
37 Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Active, not recruiting NCT02862470
38 Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples Enrolling by invitation NCT02239575
39 Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies Not yet recruiting NCT04128631
40 Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study Not yet recruiting NCT03639662

Search NIH Clinical Center for Thyroid Gland Follicular Carcinoma

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Gland Follicular Carcinoma

Anatomical Context for Thyroid Gland Follicular Carcinoma

MalaCards organs/tissues related to Thyroid Gland Follicular Carcinoma:

40
Thyroid, Lung, Endothelial, Bone, Lymph Node, Nk Cells, Brain

Publications for Thyroid Gland Follicular Carcinoma

Articles related to Thyroid Gland Follicular Carcinoma:

(show top 50) (show all 100)
# Title Authors PMID Year
1
Canine Thyroid Cancer: Molecular Characterization and Cell Line Growth in Nude Mice. 61
32081094 2020
2
Effects of recombinant canine interferon-γ injected before general anesthesia with propofol and isoflurane on natural killer cytotoxic activity during anesthesia in dogs. 61
29113646 2019
3
[Hormone-producing thyroid carcinoma in a female 10-year-old Australian Cattle Dog]. 61
29536462 2018
4
Signet Ring Cell Carcinoma of Unknown Primary Origin Detected Incidentally by Lymph Node Purification for Thyroid Carcinoma. 61
29033443 2018
5
Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. 61
27282352 2016
6
Comparative Evaluation of β-Catenin and E-Cadherin Expression in Liquid Aspiration Biopsy Specimens of Thyroid Nodules. 61
27383156 2016
7
Generation of recombinant canine interleukin-15 and evaluation of its effects on the proliferation and function of canine NK cells. 61
25890849 2015
8
Thyroid gland follicular carcinoma. 61
25738712 2015
9
Prevalence of incidental thyroid nodules in ultrasound studies of dogs with hypercalcemia (2008-2013). 61
24935646 2015
10
Clinical and imaging characteristics of orbital metastatic lesions among Egyptian patients. 61
26392748 2015
11
Papillary thyroid adenocarcinoma with occipital lobe metastasis 48 years after original diagnosis: case report. 61
23594202 2014
12
Ultrasound image-guided therapy enhances antitumor effect of cisplatin. 61
27277628 2014
13
Activation of microbubbles by short-pulsed ultrasound enhances the cytotoxic effect of cis-diamminedichloroplatinum (II) in a canine thyroid adenocarcinoma cell line in vitro. 61
22104534 2012
14
Total spondylectomy of C2: report of three cases and review of the literature. 61
21131798 2010
15
Thyroid neoplasia in captive raccoons (Procyon lotor). 61
20722264 2010
16
Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion. 61
19446000 2009
17
Unusual metastasis of the papillary thyroid adenocarcinoma. 61
19463626 2009
18
Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma. 61
23485135 2008
19
Choroidal metastasis of follicular thyroid adenocarcinoma diagnosed by 25-gauge transretinal biopsy. 61
19013920 2008
20
Total spondylectomy of C2: a new surgical technique. 61
17493408 2007
21
[Late cervicodorsal metastasis of thyroid adenocarcinoma treated by anterior cervicotomy]. 61
17203903 2006
22
Brain metastases from papillary adenocarcinoma of the thyroid. 61
17380829 2006
23
Familial risks for nonmedullary thyroid cancer. 61
16030170 2005
24
[Significance of galectin-3 and CD44v6 expression in differential diagnosis of thyroid nodules]. 61
16438854 2005
25
Paratracheal cervical mass in a dog. 61
14655107 2003
26
Gender effects in familial cancer. 61
12385016 2002
27
[How to treat a thyroid adenocarcinoma inside a branchial cyst]. 61
11965107 2002
28
A low-power, "architectural," clue to the follicular variant of papillary thyroid adenocarcinoma in aspiration biopsy. 61
10740608 2000
29
Thyroid adenocarcinoma in a bald eagle (Haliaeetus leukocephalus). 61
10572872 1999
30
Papillary thyroid adenocarcinoma arising in a thyroglossal tract remnant following excision of a thyroglossal cyst: the importance of the Sistrunk procedure. 61
10563081 1999
31
[Thyroid cancer metastasizing to the kidney. Report of a case]. 61
10095915 1999
32
Hyperthyroidism associated with a thyroid adenocarcinoma in a 21-year-old gelding. 61
9857342 1998
33
Ectopic expression of bone sialoprotein in human thyroid cancer. 61
9737356 1998
34
Papillary thyroid carcinoma associated with ulcerative colitis. 61
8977948 1996
35
[Chronic granulocytic leukemia and an organ neoplasm in the same person]. 61
9289713 1996
36
A comparison of medullary thyroid carcinoma and thyroid adenocarcinoma in dogs: a retrospective study of 38 cases. 61
7571383 1995
37
Early and long-term results after completion pneumonectomy. 61
7818323 1995
38
The frequent occurrence of thyroid tumours in aged horses. 61
8040373 1994
39
Measurement of NK activity in effector cells purified from canine peripheral lymphocytes. 61
8430495 1993
40
DNA image cytometric analysis of differentiated thyroid adenocarcinoma specimens. 61
1463115 1992
41
Enhanced expression of complement regulatory proteins on thyroid epithelial cells of Graves' disease. 61
1279944 1992
42
Cystic metastases of the neck from occult thyroid adenocarcinoma. 61
1539762 1992
43
Increased activities of thymidylate synthetase and thymidine kinase in human thyroid tumors. 61
1841732 1991
44
[Thyroid adenocarcinoma and Hashimoto's goiter]. 61
2087459 1990
45
Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. 61
2118414 1990
46
Assessment of protein kinase C isozymes by enzyme immunoassay and overexpression of type II in thyroid adenocarcinoma. 61
1696850 1990
47
[Appropriate lymph node dissection in thyroid adenocarcinoma]. 61
2621504 1989
48
[Progressive systemic sclerosis, B-cell malignant lymphoma of the ileum and thyroid adenocarcinoma]. 61
2616991 1989
49
Metastatic thyroid adenocarcinoma presenting as exophthalmos. 61
3237204 1988
50
Feline hyperthyroidism--a review. 61
16031447 1988

Variations for Thyroid Gland Follicular Carcinoma

Cosmic variations for Thyroid Gland Follicular Carcinoma:

9 (show top 50) (show all 660)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88291097 VHL thyroid,NS,carcinoma,follicular carcinoma c.232A>T p.N78Y 3:10142079-10142079 15
2 COSM131097634 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1859C>A p.T620N 14:81143917-81143917 15
3 COSM131092533 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 15
4 COSM131082578 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1867G>T p.A623S 14:81143925-81143925 15
5 COSM131082731 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 15
6 COSM131082360 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1358T>C p.M453T 14:81143416-81143416 15
7 COSM131085590 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 15
8 COSM131083920 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 15
9 COSM131084415 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 15
10 COSM85727602 TSC1 thyroid,NS,carcinoma,follicular carcinoma c.257G>T p.R86L 9:132925693-132925693 15
11 COSM94332969 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.776C>G p.A259G 7:98899743-98899743 15
12 COSM94306247 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.8716C>T p.R2906C 7:98981871-98981871 15
13 COSM94333970 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9314T>C p.I3105T 7:98984957-98984957 15
14 COSM94327035 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.4574C>T p.P1525L 7:98948267-98948267 15
15 COSM94307468 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.10775C>A p.S3592Y 7:99008440-99008440 15
16 COSM94311641 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9896G>A p.R3299H 7:98993628-98993628 15
17 COSM99622204 TP53BP1 thyroid,NS,carcinoma,follicular carcinoma c.3754C>A p.R1252S 15:43428090-43428090 15
18 COSM87898709 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 17:7674221-7674221 15
19 COSM88057483 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 17:7673745-7673745 15
20 COSM87907024 TP53 thyroid,NS,carcinoma,follicular carcinoma c.799C>T p.R267W 17:7673821-7673821 15
21 COSM87897832 TP53 thyroid,NS,carcinoma,follicular carcinoma c.725G>A p.C242Y 17:7674238-7674238 15
22 COSM87902369 TP53 thyroid,NS,carcinoma,follicular carcinoma c.1009C>T p.R337C 17:7670700-7670700 15
23 COSM87898881 TP53 thyroid,NS,carcinoma,follicular carcinoma c.578A>G p.H193R 17:7674953-7674953 15
24 COSM87898714 TP53 thyroid,NS,carcinoma,follicular carcinoma c.844C>T p.R282W 17:7673776-7673776 15
25 COSM87897745 TP53 thyroid,NS,carcinoma,follicular carcinoma c.524G>A p.R175H 17:7675088-7675088 15
26 COSM95652847 TNKS2 thyroid,NS,carcinoma,follicular carcinoma c.3037A>G p.R1013G 10:91857473-91857473 15
27 COSM90566787 TNKS thyroid,NS,carcinoma,follicular carcinoma c.1969G>C p.A657P 8:9726688-9726688 15
28 COSM107083861 TAF1 thyroid,NS,carcinoma,follicular carcinoma c.650A>T p.E217V 23:71377067-71377067 15
29 COSM90697568 STK11 thyroid,NS,carcinoma,follicular carcinoma c.662C>T p.P221L 19:1220645-1220645 15
30 COSM86759087 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.1100T>G p.F367C 23:124051203-124051203 15
31 COSM86759512 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.456C>G p.F152L 23:124042639-124042639 15
32 COSM151065421 SPTA1 thyroid,NS,carcinoma,follicular carcinoma c.2944G>T p.V982F 1:158654703-158654703 15
33 COSM99817024 SPEN thyroid,NS,carcinoma,follicular carcinoma c.971C>G p.S324* 1:15909410-15909410 15
34 COSM99809287 SPEN thyroid,NS,carcinoma,follicular carcinoma c.3793C>T p.R1265* 1:15930033-15930033 15
35 COSM86768394 SNCAIP thyroid,NS,carcinoma,follicular carcinoma c.601C>A p.L201M 5:122423197-122423197 15
36 COSM91381467 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 18:51058224-51058224 15
37 COSM91385702 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.1060G>C p.V354L 18:51065527-51065527 15
38 COSM92479962 SH2B3 thyroid,NS,carcinoma,follicular carcinoma c.640G>A p.G214R 12:111418785-111418785 15
39 COSM89623394 SF3B1 thyroid,NS,carcinoma,follicular carcinoma c.635C>T p.P212L 2:197416772-197416772 15
40 COSM103027987 SETD2 thyroid,NS,carcinoma,follicular carcinoma c.5068G>A p.G1690R 3:47098029-47098029 15
41 COSM93852061 ROS1 thyroid,NS,carcinoma,follicular carcinoma c.578T>C p.V193A 6:117397116-117397116 15
42 COSM140186576 RNF43 thyroid,NS,carcinoma,follicular carcinoma c.1082C>T p.P361L 17:58358694-58358694 15
43 COSM92347951 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 10:43120124-43120124 15
44 COSM92940024 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2461T>G p.W821G 23:47185541-47185541 15
45 COSM92935660 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.1888+1G>A p.? 23:47181867-47181867 15
46 COSM92935485 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2464C>T p.Q822* 23:47185544-47185544 15
47 COSM86627088 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 13:48459766-48459766 15
48 COSM86624126 RB1 thyroid,NS,carcinoma,follicular carcinoma c.751C>T p.R251* 13:48362847-48362847 15
49 COSM86626205 RB1 thyroid,NS,carcinoma,follicular carcinoma c.1363C>T p.R455* 13:48379624-48379624 15
50 COSM86625019 RB1 thyroid,NS,carcinoma,follicular carcinoma c.1510C>T p.Q504* 13:48381258-48381258 15

Expression for Thyroid Gland Follicular Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Follicular Carcinoma.

Pathways for Thyroid Gland Follicular Carcinoma

GO Terms for Thyroid Gland Follicular Carcinoma

Cellular components related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 TG MIR222 MIR199A1 MIR183 MIR17 MIR144

Biological processes related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.77 MIR222 MIR199A1 MIR183 MIR17 MIR144
2 thyroid hormone generation GO:0006590 9.43 TG SLC5A5
3 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.4 MIR199A1 MIR17
4 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.32 MIR199A1 MIR17
5 cellular response to gonadotropin stimulus GO:0071371 9.26 SLC5A5 PAX8
6 iodide transport GO:0015705 9.16 TG SLC5A5
7 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 TSHR PAX8
8 thyroid gland development GO:0030878 8.8 TG PAX8 NKX2-1

Molecular functions related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.35 MIR222 MIR199A1 MIR183 MIR17 MIR144
2 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8

Sources for Thyroid Gland Follicular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....